Journal profile · Medicine-Infectious Diseases
Tumour Virus Research
ISSN 2666-6790 · Elsevier · Netherlands
Tumour Virus Research: CAS Zone 2 · Medicine (2025 upgraded edition); impact factor 3.8 (journal website); fully open access; APC about USD 3,480; median 77 days to acceptance (49 articles, last 24 months); 22 articles in 2025; indexed in ESCI and Scopus.
Scope
Aims, scope and focus
Tumour Virus Research is published by Elsevier and is in Zone 2 of Medicine in the CAS Journal Ranking (2025 upgraded edition). By OpenAlex counts of its recent articles, its largest topics are Cervical Cancer and HPV Research, Viral-associated cancers and disorders and Head and Neck Cancer Studies, together about 34.1% of its articles. Its main subfields are Epidemiology. (generated from OpenAlex topic counts and CAS ranking data)
An Affiliated Journal of the World Society for VirologyTumour Virus Research aims to publish primary research and review articles covering all aspects of virally driven neoplasia, ranging from basic molecular and cancer virology including virus-associated tumour models, diagnostics, vaccines, and therapies, through to clinical, epidemiological, and public awareness aspects. This open access journal is a forum for cross disciplinary work in tumour virus research and looks to build upon the expertise and unique insights that the study of different viruses can bring to the fields of cancer prevention and therapy.Tumour Virus Research aims to publish top quality articles, describing innovative research advances in the field of human tumour virology, including Hepatitis B (HBV) and C (HCV) virus, Epstein Barr virus (EBV), Human T cell leukemia virus (HTLV), Polyoma virus (PyV), Merkel Cell Polyoma virus (MCPyV), Kaposi's Sarcoma Herpes virus (KSHV) and Papillomaviruses (PV), as well as other related animal tumour virus models.The Editors particularly wish to encourage mechanistic studies, exploring fundamental cancer mechanisms that are relevant to how viruses drive malignant progression, but which are also able to inform cancer research in general. Papers describing the use of, for example, adenoviruses or other viruses as tools for investigating tumour biology, or as preventative or therapeutic agents are welcomed.This open access publication wishes to facilitate the publication of innovative articles of broad general appeal that bring together multifaceted contributions from virologists, immunologists, epidemiologists, clinicians and public health researchers. It seeks to promote dialogue and understanding of virus-induced cancers and to have a major impact on improvements to prevention, treatment and diagnosis in virus-associated tumours. Routine descriptive or repetitious studies are discouraged.The journal welcomes original research articles, reviews, short communications, and opinion articles. Our editorial board comprises expertise across the whole of tumour virology, ranging from basic virology (cellular and molecular biology), tumour immunology and disease epidemiology, to pre-clinical and clinical studies, diagnosis, prevention and therapy, as well as public health considerations.
From the journal's Aims & Scope
Research area (LetPub): Medicine-Infectious Diseases
Editor-in-chief Dong-Yan JinPublisher website
Editorial board by country: 14 in mainland China (about 14%); most named United States 34, Mainland China 14, Germany 9, United Kingdom 7, Hong Kong, China 5 (98 members with a country) Editorial board ↗Publisher website ·
Main research topics OpenAlex counts of recent articles; shares are approximate
- Cervical Cancer and HPV ResearchMedicine22.9%
- Viral-associated cancers and disordersMedicine6%
- Head and Neck Cancer StudiesMedicine5.2%
- Virus-based gene therapy researchBiochemistry, Genetics and Molecular Biology4.8%
- Polyomavirus and related diseasesMedicine4.8%
- Hepatitis B Virus StudiesMedicine4.4%
- Diverse Scientific and Economic StudiesEconomics, Econometrics and Finance4.4%
- Biotechnology and Related FieldsMedicine4%
Rankings & indexing
CAS ranking and database indexing
CAS Journal Ranking
CAS Journal Ranking, upgraded edition (March 2025)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Virology | Zone 1 |
Top journal: noReview journal: no
CAS Xinrui Journal Ranking (March 2026)Medicine Zone 2
| Level | Category | Zone |
|---|---|---|
| Major | Medicine | Zone 2 |
| Minor | Virology | Zone 2 |
Top journal: noReview journal: not marked
CAS Journal Ranking, previous upgraded edition (December 2023)Not covered
Not covered by this edition.
Database indexing
ESCIScopusDOAJLetPub
International journal early-warning lists: not listed in any editionLetPub
Editions, and major and minor categories, are shown separately and never merged into one zone; check which edition your institution uses before you submit or report.
Metrics
Impact metrics and publication volume
Impact
- Impact factor (publisher)
- 3.8Publisher website ·
- CiteScore 2026-06
- 10.5LetPub ·
- CiteScore (publisher)
- 10.5Publisher website ·
- SJR 2026-06
- 1.69LetPub ·
- SNIP 2026-06
- 2.3LetPub ·
- h-index
- 18OpenAlex ·
- i10-index
- 38OpenAlex ·
- 2-year mean citedness
- 3.84OpenAlex ·
- Self-citation rate
- 2.6%LetPub ·
- Share of gold OA articles
- 100%LetPub ·
Volume
- Articles per year
- 21LetPub ·
Articles by year OpenAlex count · 124 in total · the current year is incomplete
| Year | Articles | Open access | Citations |
|---|---|---|---|
| 2026 | 13 | 13 | 2 |
| 2025 | 22 | 22 | 78 |
| 2024 | 32 | 32 | 177 |
| 2023 | 21 | 21 | 389 |
| 2022 | 15 | 15 | 720 |
| 2021 | 21 | 21 | 460 |
Sources count differently and were observed at different times, so each source's own value is kept; "publisher" marks figures from the journal's website.
Review & acceptance
Review time and acceptance
Review time from article dates manuscript dates registered with PubMed · to
77 daysMedian, submission to acceptance · P25–P75 47 days – 112 days
- Acceptance to online
- median 2 days (49 articles)
- Submission to online
- median 80 days
- Sample
- 49 articles with submission and acceptance dates (57 in the window); the latest was accepted on
Only articles that were accepted and published are counted, not the time spent on rejected manuscripts, so this usually runs longer than a publisher's "time to first decision".
Other sources
- Average review time (community reports)
- about 14 weeksLetPub ·
- Submission to first decision
- 2 daysPublisher website ·
- First decision after review
- 37 daysPublisher website ·
- Submission to acceptance
- 65 daysPublisher website ·
- Acceptance to publication
- 2 daysPublisher website ·
- Submission to publication (journal-reported)
- about 11 weeksDOAJ ·
- Peer review
- Single anonymous peer reviewDOAJ
Community reports come from authors' own submissions (confidence 0.5) and are not a promise from the journal; for publisher figures, the journal's own definitions apply.
Fees & open access
APC and open-access policy
Fully open accessDOAJ
Every article is open access; authors usually pay an article processing charge (APC).
| Source | APC | Fee waiver | License | Observed |
|---|---|---|---|---|
| DOAJ | USD 3,480 | Yes | CC BY, CC BY-NC, CC BY-NC-ND | |
| OpenAlex | USD 3,110 / EUR 2,910 / GBP 2,490 / JPY 385,730 | — | — | |
| LetPub | USD 900 | Yes | — | |
| Publisher website | USD 3,750 | — | — |
The journal's website is authoritative for fees; sources were observed at different times and each keeps its own value, without averaging.
Submission
Article types and submission policies (journal website)
What to prepare6 items from the author guidelines
- Abstract
- ≤ 250 words
- Keywords
- 1–7
- Reference style
- Numbered, in order of citation
- Highlights
- Optional
- Graphical abstract
- Optional
- Cover letter
- Required
Article types accepted4
- opinion articlesThe journal welcomes original research articles, reviews, short communications, and opinion articles.Length not stated
- original research articlesThe journal welcomes original research articles, reviews, short communications, and opinion articles.Length not stated
- reviewsThe journal welcomes original research articles, reviews, short communications, and opinion articles.Length not stated
- short communicationsThe journal welcomes original research articles, reviews, short communications, and opinion articles.Length not stated
Policy excerpts from the journal's websiteAI use, Authorship, Conflicts of interest, Data availability, Publication ethics, License & copyright, Open access, Peer review, Preprints
- AI use Declaration of generative AI use
Authors must declare the use of generative AI tools in the manuscript preparation process upon submission of the paper.Generative AI and AI-assisted technologies (“AI tools”) have been rapidly adopted in research and scholarly publishing, offering significant benefits while requiring clear standards for responsible and transparent use.Authors preparing a manuscript for this journal may use AI tool…
Source ↗Publisher website ·- Authorship Group authorship
Submission declaration: work not published previously (except preprint, abstract, lecture, thesis, registered report); not under consideration elsewhere; approved by all authors; not published elsewhere without consent. Model summary
Group authorship refers to the attribution of an article to a defined and named group of authors whose members have contributed to the work. Examples include research consortia, clinical trial groups, collaborative networks, task forces or working groups, expert panels or consensus groups, and participatory research groups. Group authorship must be declared on the title page at submission. When av…
Source ↗Publisher website ·- Conflicts of interest Declaration of competing interests
All authors must disclose any financial and personal relationships with other people or organizations that could inappropriately influence or bias their work. Examples of potential competing interests include:EmploymentConsultanciesStock ownershipHonorariaPaid expert testimonyPatent applications or registrationsGrants or any other fundingAffiliation with the journal as an Editor or Advisory Board …
Source ↗Publisher website ·- Data availability
Elsevier takes a neutral position on territorial disputes or jurisdictional claims. Model summary
Elsevier respects the decisions taken by its authors as to how they choose to designate territories and identify their affiliations in their published content.
Source ↗Publisher website ·- Publication ethics
Authors must follow Elsevier's Publishing Ethics Policy. Model summary
Authors must follow ethical guidelines stated in Elsevier's Publishing Ethics Policy.
Source ↗Publisher website ·- License & copyright License options
Authors will be offered open access user license options which will determine how you, and third parties, can reuse your open access article. We advise that you review these options and any funding body license requirements before selecting a license option.
Source ↗Publisher website ·- Open access Open access
Open access journal. Model summary
We refer you to our open access information page to learn about open access options for this journal.
Source ↗Publisher website ·- Peer review Peer review
Single anonymized review process; submissions initially assessed by editors, then sent to a minimum of two reviewers; editors make the decision. Model summary
This journal follows a single anonymized review process. Your submission will initially be assessed by our editors. If your submission is deemed suitable, it will typically be sent to be reviewed by a minimum of two reviewers for an independent expert assessment of the scientific quality. The decision as to whether your article is accepted or rejected for publication will be made by our editors.Re…
Source ↗Publisher website ·- Preprints Preprints
Preprint sharing allowed; does not count as prior publication; free preprint posting service on SSRN offered. Model summary
Preprint sharingAuthors may share preprints in line with Elsevier's article sharing policy. Sharing preprints, such as on a preprint server, will not count as prior publication.We advise you to read our policy on multiple, redundant or concurrent publication. In support of Open Science, this journal offers its authors a free preprint posting service on SSRN, Elsevier’s preprint and early research …
Source ↗Publisher website ·
Excerpts are quoted from the journal's website; "model summary" lines are written by Workers AI and checked against the text. The journal's website is authoritative.
Profile
Publication details and official links
- Publisher
- Elsevier
- Country or region
- Netherlands
- Language
- English
- ISSN
- 2666-6790
- Official links
- Journal homepage ↗DOAJ
- Submission system ↗Publisher website
- Author guidelines ↗DOAJ
- Aims & Scope ↗DOAJ
- Special issues ↗Publisher website
- APC information ↗DOAJ
- Fee waivers ↗DOAJ
- Open access statement ↗DOAJ
- License & copyright ↗DOAJ
- Peer review process ↗DOAJ
- Editorial board ↗DOAJ
- Plagiarism policy ↗DOAJ
FAQ
Frequently asked questions about Tumour Virus Research
What CAS zone is Tumour Virus Research in?
In the 2025 upgraded edition of the CAS Journal Ranking, Tumour Virus Research is in Zone 2 of Medicine, and in Zone 1 of the minor category Virology. In the 2026 Xinrui edition it is in Zone 2 of Medicine. Zones from different editions, and from major and minor categories, are not interchangeable.
What is the impact factor of Tumour Virus Research?
The journal's website gives an impact factor of 3.8; this is the journal's own figure, as LetPub lists none for it; CiteScore 10.5, h-index 18.
How long does peer review take at Tumour Virus Research?
Based on the dates recorded on 49 articles published between October 2024 and October 2026 (the last 24 months), the median time from submission to acceptance is 77 days (interquartile range 47–112 days); authors report an average review time of about 14 weeks. Article statistics cover accepted papers only, publisher figures follow the journal's own definitions, and community reports come from authors' own submissions; none is a promise from the journal.
What are the manuscript requirements of Tumour Virus Research?
According to the journal's author guidelines: Abstract: ≤ 250 words; Keywords: 1–7; Reference style: Numbered, in order of citation; Highlights: Optional; Graphical abstract: Optional; Cover letter: Required. A model extracted these from the author guidelines and each was checked against the text; check the latest version on the journal's website before submitting.
Where are the editorial board members of Tumour Virus Research based?
Of the 98 board members whose country the journal's board page names, 14 (about 14%) are in mainland China; the countries named most often are United States (34), Mainland China (14) and Germany (9). Counted from the institutions listed on the board page; for reference only.
Which databases index Tumour Virus Research?
According to LetPub and DOAJ records, Tumour Virus Research is indexed in ESCI, Scopus and DOAJ.
Is Tumour Virus Research open access, and what is the APC?
Tumour Virus Research is a fully open-access journal. APC about USD 3,480.
Sources and updates
The facts on this page come from LetPub, Publisher website, OpenAlex, DOAJ; every figure is tagged with its source and the date it was observed, and conflicting values are kept per source. LetPub source page: view ↗ (archived 2026-08-26). Last updated: .